Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors

Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD‐1)/programmed cell death 1 ligand 1 (PD‐L1) pathway have transformed urothelial cancer (UC) therapy. The correlation between PD‐L1 expression and ICI effectiveness is uncertain, leaving the role of PD‐L1 as a predi...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna Hernández‐Prat, Alejo Rodriguez‐Vida, Laura Cardona, Mengjuan Qin, Oriol Arpí‐Llucià, Luis Soria‐Jiménez, Sílvia Menendez, Fabricio Gerel Quimis, Miguel Galindo, Edurne Arriola, Marta Salido, Nuria Juanpere‐Rodero, Federico Rojo, Aura Muntasell, Joan Albanell, Ana Rovira, Joaquim Bellmunt
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Molecular Oncology
Subjects:
bladder cancer
HLA‐I
mTOR
PD‐L1
tumor microenvironment
Online Access:https://doi.org/10.1002/1878-0261.13699
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/1878-0261.13699

Similar Items